DEFA14A: InMed Pharma Sets 2025 Annual Meeting, Seeks Share Issuance Approval

InMed Pharmaceuticals Inc. announces its 2025 Annual General and Special Meeting to be held virtually on December 17, 2025, seeking shareholder approval for director elections, auditor appointment, and a significant share issuance under a standby equity purchase agreement.

Summary

• InMed Pharmaceuticals Inc. (the Company) will hold its 2025 Annual General and Special Meeting virtually on Wednesday, December 17, 2025, at 4:00 p.m. (PST).
• Shareholders will vote on receiving the audited financial statements for the fiscal year ended June 30, 2025, along with the auditors' report.
• The meeting includes proposals for the election of directors to hold office until the next annual meeting and the appointment of CBIZ CPAs P.C. as the auditor/independent registered public accounting firm.
• A key proposal seeks shareholder approval for the potential issuance of 20% or more of the Company's issued and outstanding common shares as of December 13, 2024, pursuant to a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., dated December 13, 2024, and amended on June 13, 2025.
• The meeting will be conducted via telephone conference, and shareholders will not be able to attend in person.
• The record date for voting eligibility is October 22, 2025, and the proxy cut-off date for submitting votes is December 15, 2025, at 4:00 p.m. (PST).

Sentiment

Score: 5

Explanation: The filing is largely procedural, announcing an upcoming annual meeting and the items to be voted on. The proposal for a significant share issuance via SEPA introduces a potential negative (dilution) but is presented as a necessary financing mechanism, leading to a neutral overall sentiment.

Positives

• The company is adhering to corporate governance requirements by holding its annual meeting and seeking necessary shareholder approvals.
• The use of notice-and-access rules for meeting materials is environmentally responsible and reduces printing and mailing costs.

Negatives

• The proposal to issue 20% or more of common shares under the SEPA could lead to significant shareholder dilution.
• The meeting is virtual-only, which may limit direct engagement for some shareholders.

Risks

• Potential significant dilution for existing shareholders if the proposal to issue 20% or more of common shares under the Standby Equity Purchase Agreement (SEPA) is approved and subsequently executed.

Future Outlook

The filing primarily outlines procedural matters for the upcoming annual meeting and does not provide specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the intention to receive audited financial statements for the fiscal year ended June 30, 2025.

Management Comments

• Management and the Board recommend a vote FOR each nominee and FOR each matter to be voted on.

Industry Context

This filing is a standard procedural notice for an annual general meeting, common across publicly traded companies. The proposal for a significant share issuance via a SEPA is a financing mechanism often used by smaller or growth-stage companies to access capital, which can be a common practice in the biotechnology or pharmaceutical industry for funding research and development or operational needs.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution due to the proposed share issuance under the SEPA. Opportunity to vote on key corporate matters including director elections and auditor appointment.

Next Steps

• Shareholders are encouraged to review the full proxy materials online at www.inmedpharma.com and www.SEDARPlus.com.
• Shareholders must submit their votes by the proxy cut-off date of December 15, 2025, at 4:00 p.m. (PST).
• The 2025 Annual General and Special Meeting will be held virtually on December 17, 2025, at 4:00 p.m. (PST).
• At the meeting, the Company will receive audited financial statements for the fiscal year ended June 30, 2025.
• Directors will be elected at the meeting.
• CBIZ CPAs P.C. will be appointed as the auditor at the meeting.
• Shareholders will vote on the SEPA share issuance proposal.

Key Dates

Keywords

InMed Pharmaceuticals, Annual General Meeting, Shareholder Meeting, Proxy Statement, SEPA, Standby Equity Purchase Agreement, Share Issuance, Dilution, Corporate Governance, Auditor Appointment, Director Election, Nasdaq Listing Rules